Another interesting study is called, -Induction of mesothelioma in p53 mouse by intraperitoneal applying of multi-wall carbon nanotube- by Atsuya Takagi, Akihiko Hirose, Tetsuji Nishimura, Nobutaka Fukumori, Akio Ogata, Norio Ohashi, Satoshi Kitajima and Jun Kanno – The Journal of Toxicological Sciences Vol. 33 (2008) , No. 1 February 105-116. We have found an excerpt: -ABSTRACT- Nanomaterials of carbon origin often form various shapes of particles in micrometer dimensions. Included in this, multi-wall carbon nanotubes (MWCNT) form fibrous or rod-shaped particles of length around 10 to 20 micrometers through an aspect ratio of greater than three. Fibrous particles on this dimension including asbestos and many man-made fibers are considered to be carcinogenic, typically inducing mesothelioma. Ideas advise that MWCNT induces mesothelioma in addition to a positive control, crocidolite (blue asbestos), when administered intraperitoneally to p53 heterozygous mice that have been considered to be understanding of asbestos. Our results highlight the possibility that carbon-made fibrous or rod-shaped micrometer particles may share the carcinogenic mechanisms postulated for asbestos. To preserve sound activity of industrialization of nanomaterials, it could be prudent to employ techniques to keep good control over experience of fibrous or rod-shaped carbon materials throughout the businesses along with the long term market before biological/ carcinogenic properties, especially within their long-term biodurability, are fully assessed.-
One interesting study is known as, -Inactivation of p16INK4a expression in malignant mesothelioma by methylation.- By Wong L, Zhou J, Anderson D, Kratzke RA. – Research Service, Minneapolis VA Infirmary, Minneapolis, MN, USA – United states. 2002 Nov;38(2):131-6. Here is an excerpt: -Abstract – The molecular mechanisms of oncogenesis in mesothelioma involve loosing negative regulators of cell growth including p16(INK4a). Absence of expression on the p16(INK4a) gene item is exhibited in almost all mesothelioma tumors and cell lines examined as of yet. Decrease in p16(INK4a) expression has also been frequently welcomed in more prevalent neoplasms such as carcinoma of the lung in addition. In the wide selection of these malignancies, including lung cancer, p16(INK4a) expression is known to be inactivated by hypermethylation of your first exon. In a very survey of ten mesothelioma cell lines, one cell line (NCI-H2596) was labeled as possessing lack of p16(INK4a) gene product following gene methylation. This methylation during these mesothelioma cells might be reversed, which results in re-expression of p16(INK4a) protein, following a remedy for the cells with cytidine analogs, which are usually known inhibitors of DNA methylation. In previous clinical studies in mesothelioma, the cytidine analog dihydro-5-azacytidine (DHAC) has been discovered to induce clinical responses in approximately 17% of patients with mesothelioma treated with this drug, including prolonged complete responses. On top of that, we identified evidence for methylation of p16(INK4a) in three of 11 resected mesothelioma tumor samples. When both cell lines and tumors are combined, inactivation of p16(INK4a) gene product expression following DNA hypermethylation was discovered in four of 21 samples (19%). I am further checking out the clinical significance of inhibition of methylation in mesothelioma by cytidine analogs. This might make a potential treatment target in certain mesothelioma tumors by inhibition of methylation.-
One interesting study is named, -Immunohistochemistry while in the distinction malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of recent antibodies- by way of a S Abutaily, B J Addis, W R Roche – J Clin Pathol 2002;55:662-668 This is an excerpt: -Abstract – Aim: The power of immunohistochemical staining in differentiating between malignant mesothelioma and pulmonary adenocarcinoma was re-examined using newly available commercial antibodies, using the purpose of increasing the sensitivity and specificity of diagnosis, and simplifying the antibody panel required. Methods: Forty one malignant mesotheliomas and 35 lung adenocarcinomas were studied. Commercial antibodies to calretinin, E-cadherin, N-cadherin, surfactant apoprotein A (SP-A), thyroid transcription factor 1 (TTF-1), thrombomodulin, and cytokeratin 5/6 were applied utilizing the streptavidin-biotin-peroxidase complex procedure on formalin fixed, paraffin wax embedded tissue. Results: E-cadherin was expressed in all of the adenocarcinomas also in 22% with the mesotheliomas. TTF-1 expression was detected in 69% belonging to the adenocarcinomas and none of the mesotheliomas. Positive staining with polyclonal anticalretinin was detected in 80% belonging to the mesotheliomas and 6% of your adenocarcinomas. N-cadherin was expressed in 78% of mesotheliomas and 26% of adenocarcinomas. Thrombomodulin was expressed in 6% of your adenocarcinomas along with 53% on the mesotheliomas. Cytokeratin 5/6 expression was detected in 6% of your adenocarcinomas and 63% belonging to the mesotheliomas. The end result were balanced with standard laboratory panel for mesothelioma diagnosis: anticarcinoembryonic antigen (anti-CEA), LeuM1, BerEP4, and HBME-1.
Conclusion: Within the antibodies found in this research, E-cadherin was 100% sensitive for pulmonary adenocarcinoma and TTF-1 was 100% specific for pulmonary adenocarcinoma. The employment of these two antibodies alone was adequate for that diagnosing 69% of adenocarcinomas and 78% of mesotheliomas. Where TTF-1 is negative and E-cadherin is positive, another panel of antibodies, including BerEP4 and LeuM1 (CD15) and antibodies directed against CEA, calretinin, cytokeratin 5/6, thrombomodulin, and N-cadherin, should be used for differentiation between malignant mesothelioma and pulmonary adenocarcinoma.-
Most of us owe a debt of gratitude to those fine researchers. If you happen to found any one of these excerpts interesting, please look into the studies with their entirety.
Monty Wrobleski is the author as soon as i’ve. For more information please click on the following links
Malignant Mesothelioma
Depuy Hip Recall Lawyer
Related Articles – Exposure to asbestos, Mesothelioma Cancer, asbestos attorney, lawyer, class action lawyers, law suit, suite, lawyers, legal firms, litigation, Treatment, ,
Email this information with a Friend!
Receive Articles exactly like it direct to the email box!Subscribe without spending a dime today!
No comments:
Post a Comment